A Study of TMC207 in Patients With Moderately Impaired Hepatic Function

The purpose of this study is to assess the pharmacokinetics (what the body does to the medication), safety and tolerability of TMC207 and its N-monodesmethyl metabolite (M2) in healthy participants an...

Lead sponsor: Tibotec BVBA•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

COMPLETEDPhase 1

A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment

NCT05624944 · Patients with Mild or Moderate Hepatic Impairment

COMPLETEDEARLY Phase 1

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

NCT04223635 · Moderate Hepatic Impairment

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 20, 2012Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment16

Start dateJan 2010

Last updatedDec 20, 2012

Condition

Moderate Hepatic Impairment

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 20, 2012Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions